Publication: The antimalarial ferroquine: From bench to clinic
Issued Date
2011-01-01
Resource Type
ISSN
17761042
1252607X
1252607X
Other identifier(s)
2-s2.0-84855268494
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Parasite. Vol.18, No.3 (2011), 207-214
Suggested Citation
C. Biot, F. Nosten, L. Fraisse, D. Ter-Minassian, J. Khalife, D. Dive The antimalarial ferroquine: From bench to clinic. Parasite. Vol.18, No.3 (2011), 207-214. doi:10.1051/parasite/2011183207 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/11390
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The antimalarial ferroquine: From bench to clinic
Author(s)
Abstract
Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.